Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib

2021 ◽  
Author(s):  
Yaogeng Wang ◽  
Rolf W. Sparidans ◽  
Jing Wang ◽  
Wenlong Li ◽  
Maria C. Lebre ◽  
...  
Keyword(s):  
Oral Availability

Improving “gut feelings” for poorly water-soluble drugs

2018 ◽  
Vol 10 (446) ◽  
pp. eaau0472 ◽  
Author(s):  
Keyue Shen
Keyword(s):  
Water Soluble ◽  
Poorly Water Soluble Drugs ◽  
Gut Feelings ◽  
Water Soluble Drugs ◽  
Poorly Water Soluble ◽  
Self Assembled ◽  
Oral Availability

A nanocarrier system self-assembled in the intestine significantly improves oral availability of poorly water-soluble drugs.

scholarly journals Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?

2020 ◽  
Vol 6 (2) ◽  
pp. 66
Author(s):  
Maria Aigner ◽  
Cornelia Lass-Flörl
Keyword(s):  
Amphotericin B ◽  
The Novel ◽  
Phase Ii Clinical Trials ◽  
Wide Range ◽  
Life Threatening ◽  
Oral Availability ◽  
Reduced Toxicity ◽  
Yeasts And Molds ◽  
Lipid Formulations ◽  
Cargo Molecule

As the oldest and for many decades the only available agent for the treatment of life-threatening invasive fungal diseases, amphotericin B (AmB) is known for its broad-spectrum fungicidal activity against a wide range of yeasts and molds. However, the main drawback of the present formulations remains its toxicity, the limited use to intravenous administration, and the higher costs associated with the better tolerated lipid formulations. The novel nanoparticle-based encochleated AmB (CAmB) formulation encapsulates, protects, and delivers its cargo molecule AmB in the interior of a calcium-phospholipid anhydrous crystal. Protecting AmB from harsh environmental conditions and gastrointestinal degradation, CAmB offers oral availability in conjunction with reduced toxicity. Matinas BioPharma, Bedminster, NJ is on the way to develop CAmB named MAT2203, currently undergoing Phase II clinical trials.

Oral Availability of Bilastine

2013 ◽  
Vol 33 (5) ◽  
pp. 375-381 ◽  
Author(s):  
B. Sádaba ◽  
A. Gómez-Guiu ◽  
J. R. Azanza ◽  
I. Ortega ◽  
R. Valiente
Keyword(s):  
Oral Availability

ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib

2021 ◽  
pp. 105850
Author(s):  
Yaogeng Wang ◽  
Rolf W. Sparidans ◽  
Sander Potters ◽  
Maria C. Lebre ◽  
Jos H. Beijnen ◽  
...  
Keyword(s):  
Oral Availability

Oral Availability of Cefadroxil Depends on ABCC3 and ABCC4

2011 ◽  
Vol 40 (3) ◽  
pp. 515-521 ◽  
Author(s):  
Dirk R. de Waart ◽  
Koen van de Wetering ◽  
Cindy Kunne ◽  
Suzanne Duijst ◽  
Coen C. Paulusma ◽  
...  
Keyword(s):  
Oral Availability

Oral availability of a poorly absorbed drug, hydrochlorothiazide, from a bioadhesive formulation in the rat

1989 ◽  
Vol 56 (2) ◽  
pp. 97-102 ◽  
Author(s):  
D. Harris ◽  
J.T. Fell ◽  
D.C. Taylor ◽  
J. Lynch ◽  
H.L. Sharma
Keyword(s):  
Oral Availability
Sign in / Sign up

Export Citation Format

Share Document